Daniel Wolfson, MD
Gastroenterology · Miami Beach, FLNPI 1124230958
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,630 of the $4,149 with a category attached, or 87.5%. It is spread thinly across 23 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,259, 4.3 times the $294 reported in 2019.
Across 121 payments — averaging $34.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$908
- Janssen Scientific Affairs, LLC$522
- Madrigal Pharmaceuticals$480
- Johnson & Johnson$450
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$267
- Intra-sana Laboratories$250
- plus $1K from 17 others
What the payments were for
- Speaking & faculty fees$2506%
- Food & beverage$3,63087%
- Education$2696%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 31 | $908 |
| Janssen Scientific Affairs, LLC | 5 | $522 |
| Madrigal Pharmaceuticals | 13 | $480 |
| Johnson & Johnson | 12 | $450 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $267 |
| Intra-sana Laboratories | 1 | $250 |
| Ardelyx, Inc. | 4 | $193 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $150 |
| Globus Medical | 1 | $139 |
| Idorsia Pharmaceuticals US Inc | 1 | $121 |
| Abbott | 5 | $96 |
| Braintree Laboratories, Inc. | 5 | $89 |
| Ipsen Biopharmaceuticals, Inc | 3 | $78 |
| Aimmune Therapeutics, Inc. | 3 | $68 |
| Pfizer | 3 | $65 |
| Novo Nordisk | 3 | $59 |
| Intercept Pharmaceuticals, Inc. | 2 | $50 |
| QOL Medical, LLC | 3 | $41 |
| Lilly USA, LLC | 2 | $36 |
| Exact Sciences | 1 | $30 |
| Eisai Inc. | 1 | $23 |
| Merck | 1 | $21 |
| Evoke Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tremfya$279
- Reltone 200 Mg$250
- Reltone 400 Mg$250
- Skyrizi$249
- IBSRELA$146
- XLIF$139
- RESMETIROM$139
- REZDIFFRA$138
- STELARA$125
- QUVIVIQ$121
- Rinvoq$120
- XIFAXAN$104
How this compares
$4,149 in reported general payments places this provider in the 55th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mesalamine | 27 | $11,626 |
| Omeprazole | 53 | $1,016 |
| Pantoprazole Sodium | 53 | $604 |
| Famotidine | 19 | $581 |
| CholestyramineCholestyramine (With Sugar) | 14 | $438 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Miami Beach
- Arin NewmanMiami Beach$716K
- Samuel GidayOrlando$2M
- Lukasz KwapiszMiami$1.2M
- Jennifer Seminerio-DiehlOrlando$1.1M
- Udayakumar NavaneethanSaint Petersburg$1.1M
- Ronen AraiCoral Springs$1.1M
- Charles SninskyGainesville$983K
- Peter DraganovGainesville$832K
- Joanna LopezMiami$670K
- Jose NietoSebring$573K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.